{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T11:03:16Z","timestamp":1784804596706,"version":"3.55.0"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T00:00:00Z","timestamp":1784764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T00:00:00Z","timestamp":1784764800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100003130","name":"Fonds Wetenschappelijk Onderzoek","doi-asserted-by":"publisher","award":["1SE9425N"],"award-info":[{"award-number":["1SE9425N"]}],"id":[{"id":"10.13039\/501100003130","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Clinical Research fund (KOOR) at the University Hospitals Leuven"},{"name":"Research council at the KU Leuven"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Patient"],"DOI":"10.1007\/s40271-026-00822-5","type":"journal-article","created":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T10:29:43Z","timestamp":1784802583000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Patient Preferences for Inflammatory Bowel Disease Treatment: Results from a Global Survey Conducted in Partnership with the European Federation of Crohn\u2019s & Ulcerative Colitis Associations"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3542-6936","authenticated-orcid":false,"given":"Elise","family":"Schoefs","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9942-3019","authenticated-orcid":false,"given":"S\u00e9verine","family":"Vermeire","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Stella","family":"De Rocchis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6197-9126","authenticated-orcid":false,"given":"Luisa","family":"Avedano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magdalena","family":"Sajak-Szczerba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8462-1469","authenticated-orcid":false,"given":"Roberto","family":"Salda\u00f1a","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noortje","family":"Straetemans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1492-0716","authenticated-orcid":false,"given":"Marc","family":"Ferrante","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8892-7075","authenticated-orcid":false,"given":"Jo\u00e3o","family":"Sabino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3898-7093","authenticated-orcid":false,"given":"Bram","family":"Verstockt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0317-1986","authenticated-orcid":false,"given":"Martina","family":"Vandebroek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Huys","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,23]]},"reference":[{"key":"822_CR1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pop.2023.03.009","author":"LP Bruner","year":"2023","unstructured":"Bruner LP, White AM, Proksell S. Inflammatory bowel disease. Prim Care Clin Office Pract. 2023. https:\/\/doi.org\/10.1016\/j.pop.2023.03.009. (W.B. Saunders;).","journal-title":"Prim Care Clin Office Pract"},{"key":"822_CR2","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/S2468-1253(19)30333-4","volume":"5","author":"S Alatab","year":"2020","unstructured":"Alatab S, Sepanlou SG, Ikuta K, Vahedi H, Bisignano C, Safiri S, et al. The global, regional, and national burden of inflammatory bowel disease in 195 countries and territories, 1990\u20132017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet Gastroenterol Hepatol. 2020;5:17\u201330. https:\/\/doi.org\/10.1016\/S2468-1253(19)30333-4. (Elsevier Ltd).","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"822_CR3","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1093\/ecco-jcc\/jjab178","volume":"16","author":"T Raine","year":"2022","unstructured":"Raine T, Bonovas S, Burisch J, Kucharzik T, Adamina M, Annese V, et al. ECCO guidelines on therapeutics in ulcerative colitis: medical treatment. J Crohns Colitis. 2022;16:2\u201317. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjab178. (Oxford University Press).","journal-title":"J Crohns Colitis"},{"key":"822_CR4","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.1093\/ecco-jcc\/jjae091","volume":"18","author":"H Gordon","year":"2024","unstructured":"Gordon H, Minozzi S, Kopylov U, Verstockt B, Chaparro M, Buskens C, et al. ECCO guidelines on therapeutics in Crohn\u2019s disease: medical treatment. J Crohns Colitis. 2024;18:1531\u201355. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjae091. (Oxford University Press (OUP)).","journal-title":"J Crohns Colitis"},{"key":"822_CR5","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1136\/gutjnl-2022-328221","volume":"72","author":"P Sudhakar","year":"2023","unstructured":"Sudhakar P, Wellens J, Verstockt B, Ferrante M, Sabino J, Vermeire S. Holistic healthcare in inflammatory bowel disease: time for patient-centric approaches? Gut. 2023;72:192\u2013204. https:\/\/doi.org\/10.1136\/gutjnl-2022-328221.","journal-title":"Gut"},{"key":"822_CR6","doi-asserted-by":"publisher","DOI":"10.1177\/17562848231218615","author":"A Kumar","year":"2023","unstructured":"Kumar A, Yassin N, Marley A, Bellato V, Foppa C, Pellino G, et al. Crossing barriers: the burden of inflammatory bowel disease across Western Europe. Ther Adv Gastroenterol. 2023. https:\/\/doi.org\/10.1177\/17562848231218615. (SAGE Publications Ltd;).","journal-title":"Ther Adv Gastroenterol"},{"key":"822_CR7","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1093\/ecco-jcc\/jjac145","volume":"17","author":"E Schoefs","year":"2022","unstructured":"Schoefs E, Vermeire S, Ferrante M, Sabino J, Lambrechts T, Avedano L, et al. What are the unmet needs and most relevant treatment outcomes according to patients with inflammatory bowel disease? A qualitative patient preference study. J Crohns Colitis. 2022;17:379\u201388. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjac145. (Oxford University Press (OUP)).","journal-title":"J Crohns Colitis"},{"key":"822_CR8","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1093\/ibd\/izx100","volume":"24","author":"SR Knowles","year":"2018","unstructured":"Knowles SR, Graff LA, Wilding H, Hewitt C, Keefer L, Mikocka-Walus A. Quality of life in inflammatory bowel disease: a systematic review and meta-analyses - Part I. Inflamm Bowel Dis. 2018;24:742\u201351. https:\/\/doi.org\/10.1093\/ibd\/izx100. (Lippincott Williams and Wilkins;).","journal-title":"Inflamm Bowel Dis"},{"key":"822_CR9","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1016\/j.crohns.2013.01.010","volume":"7","author":"J Burisch","year":"2013","unstructured":"Burisch J, Jess T, Martinato M, Lakatos PL. The burden of inflammatory bowel disease in Europe. J Crohns Colitis. 2013;7:322\u201337. https:\/\/doi.org\/10.1016\/j.crohns.2013.01.010.","journal-title":"J Crohns Colitis"},{"key":"822_CR10","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1002\/ueg2.12305","volume":"10","author":"S Vieujean","year":"2022","unstructured":"Vieujean S, D\u2019Amico F, Netter P, Danese S, Peyrin-Biroulet L. Landscape of new drugs and targets in inflammatory bowel disease. United Eur Gastroenterol J. 2022;10:1129\u201366. https:\/\/doi.org\/10.1002\/ueg2.12305. (John Wiley and Sons Inc;).","journal-title":"United Eur Gastroenterol J"},{"key":"822_CR11","doi-asserted-by":"publisher","unstructured":"The PREFER consortium. PREFER recommendations - Why, when and how to assess and use patient preferences in medical product decision-making. 2022. https:\/\/doi.org\/10.5281\/zenodo.6470918","DOI":"10.5281\/zenodo.6470918"},{"key":"822_CR12","unstructured":"European Medicines Agency. Executive summary - Patient experience data in EU medicines development and regulatory decision-making workshop [Internet]. 2022. https:\/\/www.ema.europa.eu\/en\/documents\/agenda\/agenda-multi-stakeholder-workshop-patient-experience-data-medicines-development-and-regulatory-decision-making_en.pdf. Accessed 23 Jul 2024"},{"key":"822_CR13","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1007\/s40271-019-00408-4","volume":"13","author":"JC Bouvy","year":"2020","unstructured":"Bouvy JC, Cowie L, Lovett R, Morrison D, Livingstone H, Crabb N. Use of patient preference studies in HTA decision making: A NICE perspective. Patient Auckl. 2020;13:145\u20139. https:\/\/doi.org\/10.1007\/s40271-019-00408-4. (Adis).","journal-title":"Patient Auckl"},{"key":"822_CR14","volume-title":"Medical device innovation consortium patient centered benefit-risk project report: a framework for incorporating information on patient preferences regarding benefit and risk into regulatory assessments of new medical technology [Internet]","author":"Medical Device Innovation Consortium","year":"2015","unstructured":"Medical Device Innovation Consortium. Medical device innovation consortium patient centered benefit-risk project report: a framework for incorporating information on patient preferences regarding benefit and risk into regulatory assessments of new medical technology [Internet]. Medical Device Innovation Consortium (MDIC); 2015."},{"key":"822_CR15","unstructured":"US Food and Drug Administration. Patient Preference Information (PPI) in Medical Device Decision Making [Internet]. 2023 [cited 2025 Feb 3]. https:\/\/www.fda.gov\/about-fda\/cdrh-patient-science-and-engagement-program\/patient-preference-information-ppi-medical-device-decision-making. Accessed 3 Feb 2025"},{"key":"822_CR16","unstructured":"IMI PREFER. CHMP & EUnetHTA parallel Scientific Advice: Qualification of a Framework and \u201cPoints to consider\u201d for method selection along with five methods for performing patient preference studies to inform regulatory and HTA-body medical product decision-making. 2021 Mar."},{"key":"822_CR17","doi-asserted-by":"publisher","first-page":"2889","DOI":"10.1007\/s12325-022-02143-z","volume":"39","author":"S Schubert","year":"2022","unstructured":"Schubert S, Picker N, Cavlar T, Knop J, Kahraman A, Mohl W. Inflammatory bowel disease patients\u2019 treatment preferences using a discrete choice experiment technique: The InPuT Study. Adv Ther. 2022;39:2889\u2013905. https:\/\/doi.org\/10.1007\/s12325-022-02143-z. (Adis).","journal-title":"Adv Ther"},{"key":"822_CR18","doi-asserted-by":"publisher","first-page":"263","DOI":"10.2147\/CEG.S206970","volume":"12","author":"M Boeri","year":"2019","unstructured":"Boeri M, Myers K, Ervin C, Marren A, DiBonaventura M, Cappelleri JC, et al. Patient and physician preferences for ulcerative colitis treatments in the United States. Clin Exp Gastroenterol. 2019;12:263\u201378. https:\/\/doi.org\/10.2147\/CEG.S206970.","journal-title":"Clin Exp Gastroenterol"},{"key":"822_CR19","doi-asserted-by":"publisher","first-page":"33","DOI":"10.2165\/11595390-000000000-00000","volume":"5","author":"P Hodgkins","year":"2012","unstructured":"Hodgkins P, Swinburn P, Solomon D, Yen L, Dewilde S, Lloyd A. Patient preferences for first-line oral treatment for mild-to-moderate ulcerative colitis a discrete-choice experiment. Patient Auckl. 2012;5:33\u201344. https:\/\/doi.org\/10.2165\/11595390-000000000-00000.","journal-title":"Patient Auckl"},{"key":"822_CR20","doi-asserted-by":"publisher","first-page":"2380","DOI":"10.1093\/ibd\/izae015","volume":"30","author":"G Fiorino","year":"2024","unstructured":"Fiorino G, Bent-Ennakhil N, Varriale P, Braegger F, Hoefkens E. Patient preferences for treatment attributes in inflammatory bowel disease: results from a large survey across seven European countries using a discrete choice experiment. Inflamm Bowel Dis. 2024;30:2380\u201394. https:\/\/doi.org\/10.1093\/ibd\/izae015. (Oxford University Press;).","journal-title":"Inflamm Bowel Dis"},{"key":"822_CR21","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1093\/ibd\/izae162","volume":"31","author":"JP Gisbert","year":"2025","unstructured":"Gisbert JP, Schreiber S, Siegel CA, Magro F, Jus A, Whichello C, et al. Benefit-risk trade-offs and patient preferences for therapy selection in ulcerative colitis: a multicountry preference study. Inflamm Bowel Dis. 2025;31:1281\u201394. https:\/\/doi.org\/10.1093\/ibd\/izae162. (Oxford University Press;).","journal-title":"Inflamm Bowel Dis"},{"key":"822_CR22","doi-asserted-by":"publisher","first-page":"3922","DOI":"10.1007\/s12325-025-03249-w","volume":"42","author":"M Argollo","year":"2025","unstructured":"Argollo M, An YK, Azzam N, Balderramo DC, Fadeeva O, Kuo CJ, et al. Patient preferences for treatment attributes in inflammatory bowel disease: a discrete choice experiment among patients in five Non-Western countries. Adv Ther. 2025;42:3922\u201344. https:\/\/doi.org\/10.1007\/s12325-025-03249-w. (Adis;).","journal-title":"Adv Ther"},{"key":"822_CR23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pone.0227635","volume":"15","author":"GS Hazlewood","year":"2020","unstructured":"Hazlewood GS, Pokharel G, Deardon R, Marshall DA, Bombardier C, Tomlinson G, et al. Patient preferences for maintenance therapy in Crohn\u2019s disease: a discrete-choice experiment. PLoS ONE. 2020;15:1\u201314. https:\/\/doi.org\/10.1371\/journal.pone.0227635.","journal-title":"PLoS ONE"},{"key":"822_CR24","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1080\/00365521.2022.2036808","volume":"57","author":"N Wickramasekera","year":"2022","unstructured":"Wickramasekera N, Coates E, Barr A, Lee MJ, Blackwell S, Bedford H, et al. Patient preferences for treatment in steroid resistant ulcerative colitis\u2013a discrete-choice experiment. Scand J Gastroenterol. 2022;57:797\u2013806. https:\/\/doi.org\/10.1080\/00365521.2022.2036808. (Taylor and Francis Ltd.;).","journal-title":"Scand J Gastroenterol"},{"key":"822_CR25","doi-asserted-by":"publisher","DOI":"10.3310\/RHXR5192","author":"E Coates","year":"2022","unstructured":"Coates E, Wickramasekera N, Barr A, Shackley P, Lee M, Hind D, et al. Patient preferences and current practice for adults with steroid-resistant ulcerative colitis: POPSTER mixed-methods study. Health Technol Assess. 2022. https:\/\/doi.org\/10.3310\/RHXR5192.","journal-title":"Health Technol Assess"},{"key":"822_CR26","doi-asserted-by":"publisher","DOI":"10.14309\/ajg.0000000000003397","author":"JC Yang","year":"2025","unstructured":"Yang JC, Janssen E, Wallace MJ, Sheahan A, Lynch J, Bewtra M, et al. Quantifying patient preferences for risk tolerance with novel dual biologic therapies for Inflammatory Bowel Disease. Am J Gastroenterol. 2025. https:\/\/doi.org\/10.14309\/ajg.0000000000003397.","journal-title":"Am J Gastroenterol"},{"key":"822_CR27","doi-asserted-by":"publisher","first-page":"1312","DOI":"10.1080\/00365521.2022.2085057","volume":"57","author":"S Brunet-Houdard","year":"2022","unstructured":"Brunet-Houdard S, Monmousseau F, Berthon G, Des Garets V, Laharie D, Picon L, et al. How are patients\u2019 preferences for anti-TNF influenced by quality of life? A discrete choice experiment in Crohn\u2019s disease patients. Scand J Gastroenterol. 2022;57:1312\u201320. https:\/\/doi.org\/10.1080\/00365521.2022.2085057.","journal-title":"Scand J Gastroenterol"},{"key":"822_CR28","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2024.1418874","author":"E Schoefs","year":"2024","unstructured":"Schoefs E, Vermeire S, Ferrante M, Sabino J, Verstockt B, Avedano L, et al. Patient preferences for Inflammatory Bowel Disease treatments: protocol development of a global preference survey using a discrete choice experiment. Front Med. 2024. https:\/\/doi.org\/10.3389\/fmed.2024.1418874.","journal-title":"Front Med"},{"key":"822_CR29","doi-asserted-by":"publisher","DOI":"10.1007\/s40273-018-0734-2","author":"V Soekhai","year":"2019","unstructured":"Soekhai V, de Bekker-Grob EW, Ellis AR, Vass CM. Discrete choice experiments in health economics: Past, present and future. Pharmacoeconomics. 2019. https:\/\/doi.org\/10.1007\/s40273-018-0734-2.","journal-title":"Pharmacoeconomics"},{"key":"822_CR30","volume-title":"Discrete choice methods with simulation","author":"K Train","year":"2002","unstructured":"Train K. Discrete choice methods with simulation. Cambridge University Press; 2002."},{"key":"822_CR31","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1016\/S2468-1253(21)00014-5","volume":"6","author":"B Barberio","year":"2021","unstructured":"Barberio B, Zamani M, Black CJ, Savarino EV, Ford AC. Prevalence of symptoms of anxiety and depression in patients with inflammatory bowel disease: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2021;6:359\u201370. https:\/\/doi.org\/10.1016\/S2468-1253(21)00014-5. (Elsevier Ltd;).","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"822_CR32","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/S2468-1253(16)30206-0","volume":"2","author":"DJ Gracie","year":"2017","unstructured":"Gracie DJ, Irvine AJ, Sood R, Mikocka-Walus A, Hamlin PJ, Ford AC. Effect of psychological therapy on disease activity, psychological comorbidity, and quality of life in inflammatory bowel disease: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2017;2:189\u201399. https:\/\/doi.org\/10.1016\/S2468-1253(16)30206-0. (Elsevier Ltd;).","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"822_CR33","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1053\/j.gastro.2020.12.031","volume":"160","author":"D Turner","year":"2021","unstructured":"Turner D, Ricciuto A, Lewis A, D\u2019Amico F, Dhaliwal J, Griffiths AM, et al. STRIDE-II: An update on the selecting therapeutic targets in Inflammatory Bowel Disease (STRIDE) initiative of the International Organization for the Study of IBD (IOIBD): Determining therapeutic goals for treat-to-target strategies in IBD. Gastroenterology. 2021;160:1570\u201383. https:\/\/doi.org\/10.1053\/j.gastro.2020.12.031.","journal-title":"Gastroenterology"},{"key":"822_CR34","doi-asserted-by":"publisher","first-page":"2013","DOI":"10.1053\/j.gastro.2020.07.064","volume":"159","author":"MT Abreu","year":"2020","unstructured":"Abreu MT, Sandborn WJ, Cataldi F, D\u2019Haens G, Feagan BG, Hanauer S, et al. Defining endpoints and biomarkers in Inflammatory Bowel Disease: Moving the needle through clinical trial design. Gastroenterology. 2020;159:2013-2018.e7. https:\/\/doi.org\/10.1053\/j.gastro.2020.07.064.","journal-title":"Gastroenterology"},{"key":"822_CR35","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1093\/ecco-jcc\/jjad015","volume":"17","author":"B Verstockt","year":"2023","unstructured":"Verstockt B, Pouillon L, Ballaux F, Jorissen C, Hoefkens E, Lembrechts N, et al. Patient-reported outcomes and disability are associated with histological disease activity in patients with ulcerative colitis: results from the APOLLO study. J Crohns Colitis. 2023;17:1046\u201354. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjad015. (Oxford University Press;).","journal-title":"J Crohns Colitis"},{"key":"822_CR36","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1093\/ecco-jcc\/jjac130","volume":"17","author":"E Louis","year":"2023","unstructured":"Louis E, Siegel CA, James B, Heidenreich S, Krucien N, Ghosh S. Patients with inflammatory bowel disease have heterogeneous treatment preferences that are largely determined by the avoidance of abdominal pain and side effects [P-POWER IBD Study]. J Crohns Colitis. 2023;17:231\u20139. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjac130. (Oxford University Press;).","journal-title":"J Crohns Colitis"},{"key":"822_CR37","doi-asserted-by":"publisher","unstructured":"Stacey D, Lewis KB, Smith M, Carley M, Volk R, Douglas EE, et al. Decision aids for people facing health treatment or screening decisions. Cochrane Database of Systematic Reviews. Wiley; 2024; https:\/\/doi.org\/10.1002\/14651858.CD001431.pub6","DOI":"10.1002\/14651858.CD001431.pub6"},{"key":"822_CR38","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.1016\/j.pec.2015.06.022","volume":"98","author":"AM Stiggelbout","year":"2015","unstructured":"Stiggelbout AM, Pieterse AH, De Haes JCJM. Shared decision making: concepts, evidence, and practice. Patient Educ Couns. 2015;98:1172\u20139. https:\/\/doi.org\/10.1016\/j.pec.2015.06.022. (Elsevier Ireland Ltd;).","journal-title":"Patient Educ Couns"},{"key":"822_CR39","doi-asserted-by":"publisher","unstructured":"Wehking F, Debrouwere M, Danner M, Geiger F, Buenzen C, Lewejohann JC, et al. Impact of shared decision making on healthcare in recent literature: a scoping review using a novel taxonomy. Journal of Public Health (Germany). Springer Nature; 2024. p. 2255\u201366. https:\/\/doi.org\/10.1007\/s10389-023-01962-w","DOI":"10.1007\/s10389-023-01962-w"},{"key":"822_CR40","doi-asserted-by":"publisher","unstructured":"Elwyn G, Frosch DL, Kobrin S. Implementing shared decision-making: Consider all the consequences. Implementation Science. BioMed Central Ltd.; 2016;11. https:\/\/doi.org\/10.1186\/s13012-016-0480-9","DOI":"10.1186\/s13012-016-0480-9"},{"key":"822_CR41","doi-asserted-by":"publisher","unstructured":"Gregor JC, Williamson M, Dajnowiec D, Sattin B, Sabot E, Salh B. Inflammatory bowel disease patients prioritize mucosal healing, symptom control, and pain when choosing therapies: Results of a prospective cross-sectional willingness-to-pay study. Patient Prefer Adherence. Dove Medical Press Ltd.; 2018;12:505\u201313. https:\/\/doi.org\/10.2147\/PPA.S152872","DOI":"10.2147\/PPA.S152872"},{"key":"822_CR42","doi-asserted-by":"publisher","unstructured":"Hagelund LM, Elkj\u00e6r Stallknecht S, Jensen HH. Quality of life and patient preferences among Danish patients with ulcerative colitis\u2013results from a survey study. Curr Med Res Opin. Taylor and Francis Ltd; 2020;36:771\u20139. https:\/\/doi.org\/10.1080\/03007995.2020.1716704","DOI":"10.1080\/03007995.2020.1716704"},{"key":"822_CR43","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1007\/s40271-019-00407-5","volume":"13","author":"E Louis","year":"2020","unstructured":"Louis E, Ramos-Go\u00f1i JM, Cuervo J, Kopylov U, Barreiro-de Acosta M, McCartney S, et al. A qualitative research for defining meaningful attributes for the treatment of inflammatory bowel disease from the patient perspective. Patient. 2020;13:317\u201325. https:\/\/doi.org\/10.1007\/s40271-019-00407-5.","journal-title":"Patient"},{"key":"822_CR44","doi-asserted-by":"publisher","unstructured":"Kobayashi T, Mizuno N, Sato N, Kawaguchi Y, Ikawa Y, Komorita N, et al. Patient preferences for advanced therapies in ulcerative colitis using conjoint analysis. Intest Res. Korean Association for the Study of Intestinal Diseases; 2025;23:318\u201337. https:\/\/doi.org\/10.5217\/ir.2024.00101","DOI":"10.5217\/ir.2024.00101"},{"key":"822_CR45","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1007\/s40271-020-00449-0","volume":"14","author":"E van Overbeeke","year":"2021","unstructured":"van Overbeeke E, Forrester V, Simoens S, Huys I. Use of patient preferences in health technology assessment: perspectives of Canadian, Belgian and German HTA representatives. Patient. 2021;14:119\u201328. https:\/\/doi.org\/10.1007\/s40271-020-00449-0.","journal-title":"Patient"},{"key":"822_CR46","doi-asserted-by":"publisher","unstructured":"Janssens R, Barbier L, Muller M, Cleemput I, Stoeckert I, Whichello C, et al. How can patient preferences be used and communicated in the regulatory evaluation of medicinal products? Findings and recommendations from IMI PREFER and call to action. Front Pharmacol. Frontiers Media SA; 2023;14. https:\/\/doi.org\/10.3389\/fphar.2023.1192770","DOI":"10.3389\/fphar.2023.1192770"},{"key":"822_CR47","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1016\/j.jval.2016.02.019","volume":"19","author":"M Ho","year":"2016","unstructured":"Ho M, Saha A, McCleary KK, Levitan B, Christopher S, Zandlo K, et al. A framework for incorporating patient preferences regarding benefits and risks into regulatory assessment of medical technologies. Value in Health. 2016;19:746\u201350. https:\/\/doi.org\/10.1016\/j.jval.2016.02.019.","journal-title":"Value in Health"},{"key":"822_CR48","doi-asserted-by":"crossref","unstructured":"Ryan M, Gerard K, Amaya-Amaya M. Using discrete choice experiments to value health and health care. Bateman I, editor. Appl. Health Econ. Health Policy. Dordrecht: Springer; 2008.","DOI":"10.1007\/978-1-4020-5753-3"},{"key":"822_CR49","doi-asserted-by":"publisher","unstructured":"Zhao M, G\u00f6nczi L, Lakatos PL, Burisch J. The Burden of Infl ammatory Bowel Disease in Europe in 2020. J Crohns Colitis. Oxford University Press; 2021;15:1573\u201387. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjab029.","DOI":"10.1093\/ecco-jcc\/jjab029"},{"key":"822_CR50","doi-asserted-by":"publisher","unstructured":"Burisch J, Zammit SC, Ellul P, Turcan S, Duricova D, Bortlik M, et al. Disease course of infl ammatory bowel disease unclassified in a European population-based inception cohort: An Epi-IBD study. Journal of Gastroenterology and Hepatology (Australia). Blackwell Publishing; 2019;34:996\u20131003. https:\/\/doi.org\/10.1111\/jgh.14563.","DOI":"10.1111\/jgh.14563"},{"key":"822_CR51","doi-asserted-by":"publisher","unstructured":"Hracs L, Windsor JW, Gorospe J, Cummings M, Coward S, Buie MJ, et al. Global evolution of infl ammatory bowel disease across epidemiologic stages. Nature. Nature Research; 2025;642:458\u201366. https:\/\/doi.org\/10.1038\/s41586-025-08940-0.","DOI":"10.1038\/s41586-025-08940-0"}],"container-title":["The Patient - Patient-Centered Outcomes Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40271-026-00822-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40271-026-00822-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40271-026-00822-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T10:29:46Z","timestamp":1784802586000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40271-026-00822-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,23]]},"references-count":51,"alternative-id":["822"],"URL":"https:\/\/doi.org\/10.1007\/s40271-026-00822-5","relation":{},"ISSN":["1178-1653","1178-1661"],"issn-type":[{"value":"1178-1653","type":"print"},{"value":"1178-1661","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,23]]},"assertion":[{"value":"26 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"S\u00e9verine Vermeire\n                      has received research support from AbbVie, J&J, Pfizer, Takeda, and Galapagos; and speakers\u2019 and\/or consultancy fees from AbbVie, Abivax, AbolerISPharma, AgomAb, Alimentiv, Arena Pharmaceuticals, AstraZeneca, BMS, Boehringer Ingelheim, Celgene, Cytoki Pharma, Dr Falk Pharma, Ferring, Galapagos, Genentech-Roche, Gilead, GSK, Hospira, Imidomics, Janssen, J&J, Lilly, Materia Prima, Mestag Therapeutics, MiroBio, Morphic, MrMHealth, Mundipharma, MSD, Pfizer, Prodigest, Progenity, Prometheus, Robarts Clinical Trials, Surrozen, Takeda, Theravance, Tillots\u00a0Pharma AG, VectivBio, Ventyx, and Zealand Pharma.\n                      EFCCA\n                      (\n                      Maria Stella De Rocchis, Luisa Avedano, Magdalena Sajak-Szczerba\n                      , and\n                      Roberto Salda\u00f1a\n                      work for this organization) has received funding support from AbbVie, AgomAb, Alfa Sigma, Arena, Bristol Myers Squibb, Boehringer Ingelheim, Celltrion, Ferring, Galapagos, Janssen, Lilly, MSD, Novartis\/Sandoz, Ono Pharmaceutical, Pfizer, Roche, and Takeda.\n                      Marc Ferrante\n                      has received research support from AbbVie, Biogen, EG, Janssen, Pfizer, Takeda, and Viatris; consultancy fees from AbbVie, AgomAb Therapeutics, Boehringer Ingelheim, Celgene, Celltrion, Eli Lilly, Janssen-Cilag, MRM Health, MSD, Pfizer, Takeda, and ThermoFisher; and speakers\u2019 fees from AbbVie, Biogen, Boehringer Ingelheim, Falk, Ferring, Janssen-Cilag, MSD, Pfizer, Takeda, Truvion Healthcare, and Viatris.\n                      Jo\u00e3o Sabino\n                      has received research support from Galapagos and Viatris; consultancy fees from Pfizer, Janssen, Ferring, Fresenius, AbbVie, Galapagos, Celltrion, Pharmacosmos, and Pharmanovia; and speaker\u2019s fees from Pfizer, AbbVie, Ferring, Falk, Takeda, Janssen, Fresenius, and Galapagos.\n                      Bram Verstockt\n                      has received research support from AbbVie, Biora Therapeutics, Celltrion, Landos, Pfizer, Sanofi, Sossei Heptares\/Nxera, and Takeda; consultancy fees from AbbVie, Alfasigma, Alimentiv, Anaptys Bio, Applied Strategic, AstraZeneca, Atheneum, BenevolentAI, Biora Therapeutics, Boxer Capital, Bristol Myers Squibb, Domain Therapeutics, Eli Lily, Galapagos, Guidepont, Landos, Merck, Mirador Therapeutics, Mylan, Nxera, Inotrem, Ipsos, Johnson and Johnson, Pfizer, Sandoz, Sanofi, Santa Ana Bio, Sapphire Therapeutics, Sosei Heptares, Takeda, Tillots Pharma, and Viatris; speaker\u2019s fees from AbbVie, Agomab, Alfasigma, Biogen, Bristol Myers Squibb, Celltrion, Eli Lily, Falk, Ferring, Galapagos, Materia Prima, Johnson and Johnson, Pfizer, Sandoz, Takeda, Tillots Pharma, Truvion, and Viatris; and stock options from Vagustim and Thethis Pharma.\n                      Isabelle Huys\n                      has received research support from Bristol Myers Squibb.\n                      Elise Schoefs\n                      ,\n                      Noortje Straetemans\n                      , and\n                      Martina Vandebroek\n                      have no conflicts to declare.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethics approval was granted by the Ethics Committee Research UZ\/KU Leuven to conduct the study (S65998).","order":2,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":3,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":4,"name":"Ethics","label":"Consent to publish","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors were involved in the design of the study. ES designed the study materials, which were discussed and reviewed by all authors. ES, SV, MSDR, LA, MS, RS, NS, MF, JS, and BV were involved in the recruitment of the participants. ES and MV analyzed the results. ES produced the first draft of the manuscript, which was subsequently revised and finalized with all authors. All the authors have read and approved the final manuscript.","order":5,"name":"Ethics","label":"Author contributions","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The data of the survey is not publicly available because it contains personal information that could compromise participants\u2019 privacy and consent. Requests to access the datasets should be directed to elise.schoefs@kuleuven.be.","order":6,"name":"Ethics","label":"Data availability statement","group":{"name":"EthicsHeading","label":"Declarations"}}]}}